

Review of: "Measuring the efficacy of a vaccine during an epidemic"

Adnan Sarwar

Potential competing interests: No potential competing interests to declare.

Comments for authors:

Can you provide more detail on the methods used to estimate the underestimation of vaccine efficacy? Were statistical models used to account for confounding factors?

It would be helpful to provide more context on the vaccines analyzed in this study. Were all COVID-19 vaccines included, or only a subset? Were any other vaccines studied as well?

The abstract mentions that the underestimation of vaccine efficacy grows with the severity of the epidemic. Can you provide a more detailed explanation of how this relationship was established? What measures were used to quantify epidemic severity?

Were there any limitations to the data used in this study, such as limitations in the accuracy of reported vaccine efficacy or limitations in the data sources used to estimate epidemic severity? If so, how were these limitations addressed in the analysis?

Lastly, can you discuss the implications of these findings for vaccine development and public health policy? How can we ensure that vaccine efficacy is accurately measured during epidemics, particularly when clinical trials are conducted under time pressure?